Personalized mRNA vaccine plus Keytruda lowers melanoma recurrence risk in Phase 3 trial

A personalized mRNA vaccine plus Keytruda lowers melanoma recurrence risk, Amgen’s Imdelltra plus Imfinzi cuts the risk of death by 58% in small cell lung cancer, and U.S. measles cases reach 4,588.